The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors
Zhen-Xin Zeng, Jiayi Wu, Junyi Wu, Yinan Li, Yang-Kai Fu, Zhi‐Bo Zhang, De-Yi Liu, Li Han, Xiang-Ye Ou, Shao-Wu Zhuang, Mao-Lin Yan
Topics & Concepts
MedicineInternal medicineHepatocellular carcinomaCohortHepatologyProportional hazards modelConfidence intervalLenvatinibTranscatheter arterial chemoembolizationOncologyGastroenterologySorafenibHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesPancreatic and Hepatic Oncology Research